nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0822	0.137	CbGbCtD
Dextroamphetamine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0773	0.129	CbGbCtD
Dextroamphetamine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0773	0.129	CbGbCtD
Dextroamphetamine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0699	0.116	CbGbCtD
Dextroamphetamine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0699	0.116	CbGbCtD
Dextroamphetamine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0603	0.1	CbGbCtD
Dextroamphetamine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0585	0.0974	CbGbCtD
Dextroamphetamine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0529	0.0881	CbGbCtD
Dextroamphetamine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0529	0.0881	CbGbCtD
Dextroamphetamine—SLC6A3—nerve—acquired immunodeficiency syndrome	0.00541	0.0805	CbGeAlD
Dextroamphetamine—SLC18A2—blood plasma—acquired immunodeficiency syndrome	0.00541	0.0805	CbGeAlD
Dextroamphetamine—TAAR1—lung—acquired immunodeficiency syndrome	0.00511	0.0761	CbGeAlD
Dextroamphetamine—TAAR1—nervous system—acquired immunodeficiency syndrome	0.00473	0.0704	CbGeAlD
Dextroamphetamine—TAAR1—central nervous system—acquired immunodeficiency syndrome	0.00456	0.0678	CbGeAlD
Dextroamphetamine—SLC6A2—nerve—acquired immunodeficiency syndrome	0.00436	0.0649	CbGeAlD
Dextroamphetamine—Amphetamine—CARTPT—acquired immunodeficiency syndrome	0.0036	0.377	CrCbGaD
Dextroamphetamine—L-Phenylalanine—TAT—acquired immunodeficiency syndrome	0.00329	0.345	CrCbGaD
Dextroamphetamine—SLC18A2—digestive system—acquired immunodeficiency syndrome	0.00208	0.0309	CbGeAlD
Dextroamphetamine—SLC18A2—blood—acquired immunodeficiency syndrome	0.00198	0.0295	CbGeAlD
Dextroamphetamine—SLC18A2—vagina—acquired immunodeficiency syndrome	0.00184	0.0273	CbGeAlD
Dextroamphetamine—Pseudoephedrine—IL2—acquired immunodeficiency syndrome	0.00182	0.19	CrCbGaD
Dextroamphetamine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00181	0.0269	CbGeAlD
Dextroamphetamine—SLC18A2—lung—acquired immunodeficiency syndrome	0.00174	0.0258	CbGeAlD
Dextroamphetamine—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.00162	0.0242	CbGeAlD
Dextroamphetamine—SLC18A2—nervous system—acquired immunodeficiency syndrome	0.00161	0.0239	CbGeAlD
Dextroamphetamine—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.00156	0.0233	CbGeAlD
Dextroamphetamine—SLC18A2—central nervous system—acquired immunodeficiency syndrome	0.00155	0.023	CbGeAlD
Dextroamphetamine—SLC6A3—spinal cord—acquired immunodeficiency syndrome	0.00144	0.0215	CbGeAlD
Dextroamphetamine—SLC6A3—lung—acquired immunodeficiency syndrome	0.00131	0.0195	CbGeAlD
Dextroamphetamine—ADRA1B—brain—acquired immunodeficiency syndrome	0.00124	0.0185	CbGeAlD
Dextroamphetamine—SLC18A2—brain—acquired immunodeficiency syndrome	0.00123	0.0183	CbGeAlD
Dextroamphetamine—SLC6A3—nervous system—acquired immunodeficiency syndrome	0.00122	0.0181	CbGeAlD
Dextroamphetamine—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.00119	0.0178	CbGeAlD
Dextroamphetamine—SLC18A2—lymph node—acquired immunodeficiency syndrome	0.00119	0.0177	CbGeAlD
Dextroamphetamine—SLC6A3—central nervous system—acquired immunodeficiency syndrome	0.00117	0.0174	CbGeAlD
Dextroamphetamine—ADRA1A—blood—acquired immunodeficiency syndrome	0.00112	0.0167	CbGeAlD
Dextroamphetamine—SLC6A2—lung—acquired immunodeficiency syndrome	0.00106	0.0158	CbGeAlD
Dextroamphetamine—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000981	0.0146	CbGeAlD
Dextroamphetamine—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000945	0.0141	CbGeAlD
Dextroamphetamine—SLC6A3—brain—acquired immunodeficiency syndrome	0.00093	0.0138	CbGeAlD
Dextroamphetamine—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.000912	0.0136	CbGeAlD
Dextroamphetamine—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.000878	0.0131	CbGeAlD
Dextroamphetamine—SLC6A2—brain—acquired immunodeficiency syndrome	0.00075	0.0112	CbGeAlD
Dextroamphetamine—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000725	0.0108	CbGeAlD
Dextroamphetamine—ADRA1A—brain—acquired immunodeficiency syndrome	0.000697	0.0104	CbGeAlD
Dextroamphetamine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000695	0.0103	CbGeAlD
Dextroamphetamine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000662	0.00985	CbGeAlD
Dextroamphetamine—Pseudoephedrine—TNF—acquired immunodeficiency syndrome	0.000614	0.0642	CrCbGaD
Dextroamphetamine—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000564	0.00175	CcSEcCtD
Dextroamphetamine—Chest pain—Efavirenz—acquired immunodeficiency syndrome	0.000564	0.00175	CcSEcCtD
Dextroamphetamine—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000564	0.00175	CcSEcCtD
Dextroamphetamine—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000563	0.00175	CcSEcCtD
Dextroamphetamine—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000562	0.00175	CcSEcCtD
Dextroamphetamine—Anxiety—Efavirenz—acquired immunodeficiency syndrome	0.000562	0.00175	CcSEcCtD
Dextroamphetamine—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000561	0.00174	CcSEcCtD
Dextroamphetamine—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000561	0.00174	CcSEcCtD
Dextroamphetamine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00056	0.00174	CcSEcCtD
Dextroamphetamine—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.00056	0.00174	CcSEcCtD
Dextroamphetamine—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000559	0.00174	CcSEcCtD
Dextroamphetamine—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000559	0.00174	CcSEcCtD
Dextroamphetamine—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000558	0.00173	CcSEcCtD
Dextroamphetamine—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000556	0.00173	CcSEcCtD
Dextroamphetamine—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000554	0.00172	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000553	0.00172	CcSEcCtD
Dextroamphetamine—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000551	0.00171	CcSEcCtD
Dextroamphetamine—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000551	0.00171	CcSEcCtD
Dextroamphetamine—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000551	0.00171	CcSEcCtD
Dextroamphetamine—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000549	0.00171	CcSEcCtD
Dextroamphetamine—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000548	0.00171	CcSEcCtD
Dextroamphetamine—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000547	0.0017	CcSEcCtD
Dextroamphetamine—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000547	0.0017	CcSEcCtD
Dextroamphetamine—Anorexia—Indinavir—acquired immunodeficiency syndrome	0.000545	0.0017	CcSEcCtD
Dextroamphetamine—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000541	0.00168	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00054	0.00168	CcSEcCtD
Dextroamphetamine—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.000539	0.00168	CcSEcCtD
Dextroamphetamine—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.000538	0.00167	CcSEcCtD
Dextroamphetamine—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000537	0.00167	CcSEcCtD
Dextroamphetamine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000537	0.008	CbGeAlD
Dextroamphetamine—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000534	0.00166	CcSEcCtD
Dextroamphetamine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000531	0.00165	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000531	0.00165	CcSEcCtD
Dextroamphetamine—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.00053	0.00165	CcSEcCtD
Dextroamphetamine—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000528	0.00164	CcSEcCtD
Dextroamphetamine—Tension—Lamivudine—acquired immunodeficiency syndrome	0.000528	0.00164	CcSEcCtD
Dextroamphetamine—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000527	0.00164	CcSEcCtD
Dextroamphetamine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000527	0.00164	CcSEcCtD
Dextroamphetamine—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000526	0.00164	CcSEcCtD
Dextroamphetamine—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000526	0.00164	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000523	0.00163	CcSEcCtD
Dextroamphetamine—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.000522	0.00162	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000522	0.00162	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000521	0.00162	CcSEcCtD
Dextroamphetamine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000518	0.00161	CcSEcCtD
Dextroamphetamine—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000518	0.00161	CcSEcCtD
Dextroamphetamine—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000518	0.00161	CcSEcCtD
Dextroamphetamine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000517	0.0077	CbGeAlD
Dextroamphetamine—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000517	0.00161	CcSEcCtD
Dextroamphetamine—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000515	0.0016	CcSEcCtD
Dextroamphetamine—Rash—Didanosine—acquired immunodeficiency syndrome	0.000514	0.0016	CcSEcCtD
Dextroamphetamine—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000514	0.0016	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000513	0.0016	CcSEcCtD
Dextroamphetamine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000513	0.0016	CcSEcCtD
Dextroamphetamine—Headache—Didanosine—acquired immunodeficiency syndrome	0.00051	0.00159	CcSEcCtD
Dextroamphetamine—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00051	0.00159	CcSEcCtD
Dextroamphetamine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000509	0.00158	CcSEcCtD
Dextroamphetamine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000508	0.00158	CcSEcCtD
Dextroamphetamine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000508	0.00158	CcSEcCtD
Dextroamphetamine—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000507	0.00158	CcSEcCtD
Dextroamphetamine—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000506	0.00157	CcSEcCtD
Dextroamphetamine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000504	0.00157	CcSEcCtD
Dextroamphetamine—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000504	0.00157	CcSEcCtD
Dextroamphetamine—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000503	0.00157	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000503	0.00156	CcSEcCtD
Dextroamphetamine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000501	0.00156	CcSEcCtD
Dextroamphetamine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.0005	0.00156	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.0005	0.00155	CcSEcCtD
Dextroamphetamine—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000499	0.00155	CcSEcCtD
Dextroamphetamine—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000497	0.00155	CcSEcCtD
Dextroamphetamine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000497	0.00155	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000494	0.00154	CcSEcCtD
Dextroamphetamine—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000493	0.00153	CcSEcCtD
Dextroamphetamine—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000493	0.00153	CcSEcCtD
Dextroamphetamine—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000491	0.00153	CcSEcCtD
Dextroamphetamine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000489	0.00152	CcSEcCtD
Dextroamphetamine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000489	0.00152	CcSEcCtD
Dextroamphetamine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000488	0.00152	CcSEcCtD
Dextroamphetamine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000488	0.00152	CcSEcCtD
Dextroamphetamine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000488	0.00152	CcSEcCtD
Dextroamphetamine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000487	0.00151	CcSEcCtD
Dextroamphetamine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000486	0.00151	CcSEcCtD
Dextroamphetamine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000486	0.00151	CcSEcCtD
Dextroamphetamine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000485	0.00151	CcSEcCtD
Dextroamphetamine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000484	0.00151	CcSEcCtD
Dextroamphetamine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000484	0.00151	CcSEcCtD
Dextroamphetamine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000482	0.0015	CcSEcCtD
Dextroamphetamine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.00048	0.00149	CcSEcCtD
Dextroamphetamine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.00048	0.00149	CcSEcCtD
Dextroamphetamine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000478	0.00149	CcSEcCtD
Dextroamphetamine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000477	0.00148	CcSEcCtD
Dextroamphetamine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000476	0.00148	CcSEcCtD
Dextroamphetamine—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.00047	0.00146	CcSEcCtD
Dextroamphetamine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000469	0.00146	CcSEcCtD
Dextroamphetamine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000469	0.00146	CcSEcCtD
Dextroamphetamine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000468	0.00146	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000468	0.00145	CcSEcCtD
Dextroamphetamine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000468	0.00145	CcSEcCtD
Dextroamphetamine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000467	0.00145	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000466	0.00145	CcSEcCtD
Dextroamphetamine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000466	0.00145	CcSEcCtD
Dextroamphetamine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000466	0.00145	CcSEcCtD
Dextroamphetamine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000466	0.00145	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000462	0.00144	CcSEcCtD
Dextroamphetamine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000462	0.00144	CcSEcCtD
Dextroamphetamine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000462	0.00144	CcSEcCtD
Dextroamphetamine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000462	0.00144	CcSEcCtD
Dextroamphetamine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000461	0.00143	CcSEcCtD
Dextroamphetamine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000461	0.00143	CcSEcCtD
Dextroamphetamine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.00046	0.00143	CcSEcCtD
Dextroamphetamine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000459	0.00143	CcSEcCtD
Dextroamphetamine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000458	0.00142	CcSEcCtD
Dextroamphetamine—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000457	0.00142	CcSEcCtD
Dextroamphetamine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000456	0.00142	CcSEcCtD
Dextroamphetamine—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000456	0.00142	CcSEcCtD
Dextroamphetamine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000455	0.00142	CcSEcCtD
Dextroamphetamine—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000454	0.00141	CcSEcCtD
Dextroamphetamine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000452	0.00141	CcSEcCtD
Dextroamphetamine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000452	0.00141	CcSEcCtD
Dextroamphetamine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000451	0.0014	CcSEcCtD
Dextroamphetamine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00045	0.0014	CcSEcCtD
Dextroamphetamine—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000449	0.0014	CcSEcCtD
Dextroamphetamine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000448	0.00139	CcSEcCtD
Dextroamphetamine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000447	0.00139	CcSEcCtD
Dextroamphetamine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000447	0.00139	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000446	0.00139	CcSEcCtD
Dextroamphetamine—Rash—Stavudine—acquired immunodeficiency syndrome	0.000446	0.00139	CcSEcCtD
Dextroamphetamine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000446	0.00139	CcSEcCtD
Dextroamphetamine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000446	0.00139	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000445	0.00138	CcSEcCtD
Dextroamphetamine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000445	0.00138	CcSEcCtD
Dextroamphetamine—Headache—Stavudine—acquired immunodeficiency syndrome	0.000443	0.00138	CcSEcCtD
Dextroamphetamine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000443	0.00138	CcSEcCtD
Dextroamphetamine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000442	0.00137	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000442	0.00137	CcSEcCtD
Dextroamphetamine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000441	0.00137	CcSEcCtD
Dextroamphetamine—Rash—Abacavir—acquired immunodeficiency syndrome	0.000439	0.00137	CcSEcCtD
Dextroamphetamine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000439	0.00137	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000439	0.00137	CcSEcCtD
Dextroamphetamine—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000439	0.00136	CcSEcCtD
Dextroamphetamine—Headache—Abacavir—acquired immunodeficiency syndrome	0.000437	0.00136	CcSEcCtD
Dextroamphetamine—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000436	0.00136	CcSEcCtD
Dextroamphetamine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000435	0.00135	CcSEcCtD
Dextroamphetamine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000432	0.00134	CcSEcCtD
Dextroamphetamine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000429	0.00133	CcSEcCtD
Dextroamphetamine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000427	0.00133	CcSEcCtD
Dextroamphetamine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000427	0.00133	CcSEcCtD
Dextroamphetamine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000426	0.00133	CcSEcCtD
Dextroamphetamine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000425	0.00132	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000424	0.00132	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000423	0.00131	CcSEcCtD
Dextroamphetamine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000421	0.00131	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000421	0.00131	CcSEcCtD
Dextroamphetamine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000421	0.00131	CcSEcCtD
Dextroamphetamine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000421	0.00131	CcSEcCtD
Dextroamphetamine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00042	0.00131	CcSEcCtD
Dextroamphetamine—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000418	0.0013	CcSEcCtD
Dextroamphetamine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000416	0.00129	CcSEcCtD
Dextroamphetamine—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000416	0.00129	CcSEcCtD
Dextroamphetamine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000414	0.00129	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000413	0.00128	CcSEcCtD
Dextroamphetamine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000412	0.00128	CcSEcCtD
Dextroamphetamine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000411	0.00611	CbGeAlD
Dextroamphetamine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000411	0.00128	CcSEcCtD
Dextroamphetamine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00041	0.00128	CcSEcCtD
Dextroamphetamine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.00041	0.00128	CcSEcCtD
Dextroamphetamine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000409	0.00127	CcSEcCtD
Dextroamphetamine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000409	0.00127	CcSEcCtD
Dextroamphetamine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000409	0.00127	CcSEcCtD
Dextroamphetamine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000409	0.00127	CcSEcCtD
Dextroamphetamine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000407	0.00126	CcSEcCtD
Dextroamphetamine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000405	0.00126	CcSEcCtD
Dextroamphetamine—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.0004	0.00124	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000398	0.00124	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000397	0.00124	CcSEcCtD
Dextroamphetamine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000397	0.00123	CcSEcCtD
Dextroamphetamine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000397	0.00123	CcSEcCtD
Dextroamphetamine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000393	0.00122	CcSEcCtD
Dextroamphetamine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000391	0.00122	CcSEcCtD
Dextroamphetamine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000391	0.00122	CcSEcCtD
Dextroamphetamine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000391	0.00122	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000391	0.00122	CcSEcCtD
Dextroamphetamine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.00039	0.00121	CcSEcCtD
Dextroamphetamine—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000388	0.00121	CcSEcCtD
Dextroamphetamine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000388	0.00121	CcSEcCtD
Dextroamphetamine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000387	0.0012	CcSEcCtD
Dextroamphetamine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000386	0.0012	CcSEcCtD
Dextroamphetamine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000385	0.0012	CcSEcCtD
Dextroamphetamine—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000382	0.00119	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000381	0.00118	CcSEcCtD
Dextroamphetamine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.00038	0.00118	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000379	0.00118	CcSEcCtD
Dextroamphetamine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000378	0.00118	CcSEcCtD
Dextroamphetamine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000378	0.00118	CcSEcCtD
Dextroamphetamine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000378	0.00118	CcSEcCtD
Dextroamphetamine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000378	0.00118	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000376	0.00117	CcSEcCtD
Dextroamphetamine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000375	0.00117	CcSEcCtD
Dextroamphetamine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000371	0.00115	CcSEcCtD
Dextroamphetamine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.00037	0.00115	CcSEcCtD
Dextroamphetamine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000366	0.00114	CcSEcCtD
Dextroamphetamine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000365	0.00114	CcSEcCtD
Dextroamphetamine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000364	0.00113	CcSEcCtD
Dextroamphetamine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000364	0.00113	CcSEcCtD
Dextroamphetamine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000364	0.00113	CcSEcCtD
Dextroamphetamine—Rash—Indinavir—acquired immunodeficiency syndrome	0.000361	0.00112	CcSEcCtD
Dextroamphetamine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00036	0.00112	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000359	0.00112	CcSEcCtD
Dextroamphetamine—Headache—Indinavir—acquired immunodeficiency syndrome	0.000358	0.00111	CcSEcCtD
Dextroamphetamine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000357	0.00111	CcSEcCtD
Dextroamphetamine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000354	0.0011	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000352	0.0011	CcSEcCtD
Dextroamphetamine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000349	0.00108	CcSEcCtD
Dextroamphetamine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000347	0.00108	CcSEcCtD
Dextroamphetamine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000347	0.00108	CcSEcCtD
Dextroamphetamine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000344	0.00107	CcSEcCtD
Dextroamphetamine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000343	0.00107	CcSEcCtD
Dextroamphetamine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000342	0.00106	CcSEcCtD
Dextroamphetamine—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000341	0.00106	CcSEcCtD
Dextroamphetamine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.00034	0.00106	CcSEcCtD
Dextroamphetamine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00034	0.00106	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000339	0.00105	CcSEcCtD
Dextroamphetamine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000338	0.00105	CcSEcCtD
Dextroamphetamine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.00033	0.00103	CcSEcCtD
Dextroamphetamine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000329	0.00102	CcSEcCtD
Dextroamphetamine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000327	0.00102	CcSEcCtD
Dextroamphetamine—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000326	0.00101	CcSEcCtD
Dextroamphetamine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000326	0.00101	CcSEcCtD
Dextroamphetamine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000324	0.00101	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000323	0.00101	CcSEcCtD
Dextroamphetamine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000321	0.000998	CcSEcCtD
Dextroamphetamine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000316	0.000983	CcSEcCtD
Dextroamphetamine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000315	0.00098	CcSEcCtD
Dextroamphetamine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000315	0.000979	CcSEcCtD
Dextroamphetamine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000307	0.000955	CcSEcCtD
Dextroamphetamine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000304	0.000946	CcSEcCtD
Dextroamphetamine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000304	0.000945	CcSEcCtD
Dextroamphetamine—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000301	0.000937	CcSEcCtD
Dextroamphetamine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000301	0.000937	CcSEcCtD
Dextroamphetamine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.0003	0.000934	CcSEcCtD
Dextroamphetamine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000299	0.000931	CcSEcCtD
Dextroamphetamine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000293	0.00091	CcSEcCtD
Dextroamphetamine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00029	0.000903	CcSEcCtD
Dextroamphetamine—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00029	0.000902	CcSEcCtD
Dextroamphetamine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00029	0.000901	CcSEcCtD
Dextroamphetamine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000288	0.000897	CcSEcCtD
Dextroamphetamine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000284	0.000883	CcSEcCtD
Dextroamphetamine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000279	0.000868	CcSEcCtD
Dextroamphetamine—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000277	0.000861	CcSEcCtD
Dextroamphetamine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000276	0.00086	CcSEcCtD
Dextroamphetamine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000275	0.000855	CcSEcCtD
Dextroamphetamine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000273	0.00085	CcSEcCtD
Dextroamphetamine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000261	0.000811	CcSEcCtD
Dextroamphetamine—Nateglinide—ALB—acquired immunodeficiency syndrome	0.000227	0.0237	CrCbGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	3.61e-05	0.0589	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	2.75e-05	0.0449	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	2.18e-05	0.0357	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	1.98e-05	0.0323	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	1.66e-05	0.0272	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	1.5e-05	0.0246	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	1.41e-05	0.023	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	1.35e-05	0.0221	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	1.22e-05	0.02	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	1.15e-05	0.0188	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	1.15e-05	0.0188	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	1.03e-05	0.0168	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	9.3e-06	0.0152	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	9.12e-06	0.0149	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	8.74e-06	0.0143	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	8.74e-06	0.0143	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	8.73e-06	0.0143	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.54e-06	0.014	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.33e-06	0.0136	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	8.1e-06	0.0132	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.87e-06	0.0129	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.72e-06	0.0126	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	6.95e-06	0.0114	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Monoamine Transport—TNF—acquired immunodeficiency syndrome	6.73e-06	0.011	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.65e-06	0.0109	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	6.17e-06	0.0101	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.99e-06	0.00979	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Monoamine Transport—TNF—acquired immunodeficiency syndrome	5.96e-06	0.00974	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	5.53e-06	0.00903	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.27e-06	0.00862	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.25e-06	0.00859	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.04e-06	0.00824	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.04e-06	0.00824	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	5e-06	0.00817	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.94e-06	0.00807	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.94e-06	0.00807	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	4.91e-06	0.00802	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.77e-06	0.0078	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.56e-06	0.00746	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.49e-06	0.00733	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.49e-06	0.00733	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	4.44e-06	0.00726	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	4.21e-06	0.00688	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	3.81e-06	0.00622	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.76e-06	0.00614	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	3.74e-06	0.00611	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.7e-06	0.00605	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	3.6e-06	0.00589	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	3.56e-06	0.00583	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.41e-06	0.00558	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.41e-06	0.00558	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.39e-06	0.00554	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.39e-06	0.00553	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	3.38e-06	0.00553	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.36e-06	0.00549	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	3.2e-06	0.00523	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.17e-06	0.00518	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	3.17e-06	0.00518	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.12e-06	0.00509	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.09e-06	0.00505	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.07e-06	0.00502	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.03e-06	0.00496	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.01e-06	0.00492	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	2.9e-06	0.00475	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	2.9e-06	0.00475	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.82e-06	0.00461	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	2.74e-06	0.00448	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.65e-06	0.00433	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.65e-06	0.00433	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.6e-06	0.00425	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	2.58e-06	0.00421	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	2.58e-06	0.00421	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.35e-06	0.00384	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.32e-06	0.0038	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.31e-06	0.00377	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.21e-06	0.00361	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.21e-06	0.00361	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.21e-06	0.00361	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.16e-06	0.00353	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.13e-06	0.00348	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.11e-06	0.00344	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.09e-06	0.00341	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.06e-06	0.00337	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.02e-06	0.00329	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.99e-06	0.00325	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.99e-06	0.00325	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.96e-06	0.00321	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.96e-06	0.00321	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.96e-06	0.00321	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.96e-06	0.0032	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.95e-06	0.00319	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.92e-06	0.00314	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	1.89e-06	0.00309	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.87e-06	0.00306	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.82e-06	0.00297	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.78e-06	0.0029	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.77e-06	0.00289	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.73e-06	0.00284	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.68e-06	0.00275	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.61e-06	0.00263	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.52e-06	0.00248	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.49e-06	0.00244	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.35e-06	0.0022	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.33e-06	0.00218	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.33e-06	0.00217	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.28e-06	0.00209	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.28e-06	0.00209	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.25e-06	0.00204	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.25e-06	0.00204	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.21e-06	0.00197	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.21e-06	0.00197	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.19e-06	0.00194	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.18e-06	0.00193	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.15e-06	0.00189	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.13e-06	0.00185	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.13e-06	0.00185	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.13e-06	0.00185	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.13e-06	0.00185	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.11e-06	0.00181	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.11e-06	0.00181	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.08e-06	0.00177	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.07e-06	0.00175	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.05e-06	0.00171	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.04e-06	0.00171	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.03e-06	0.00168	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.02e-06	0.00168	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.01e-06	0.00165	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.01e-06	0.00165	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.6e-07	0.00157	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.5e-07	0.00155	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.36e-07	0.00153	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	9.13e-07	0.00149	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.63e-07	0.00141	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.56e-07	0.0014	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.5e-07	0.00139	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	8.44e-07	0.00138	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	8.32e-07	0.00136	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	8.11e-07	0.00132	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.88e-07	0.00129	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.78e-07	0.00127	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	7.67e-07	0.00125	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	7.61e-07	0.00124	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	7.55e-07	0.00123	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.13e-07	0.00117	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7e-07	0.00114	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.91e-07	0.00113	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.7e-07	0.0011	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.7e-07	0.0011	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.33e-07	0.00103	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.17e-07	0.00101	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.95e-07	0.000973	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.95e-07	0.000973	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.1e-07	0.000833	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.02e-07	0.000821	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.95e-07	0.000809	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.59e-07	0.000751	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.53e-07	0.00074	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.49e-07	0.000734	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.46e-07	0.000729	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.39e-07	0.000718	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.08e-07	0.000667	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.99e-07	0.000652	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.65e-07	0.000434	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.64e-07	0.000432	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.36e-07	0.000385	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.35e-07	0.000383	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	2.11e-07	0.000344	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.56e-07	0.000255	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.39e-07	0.000226	CbGpPWpGaD
